Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Hampshire Health Report.
Press releases published on April 1, 2025
Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025
GlobeNewswire
·
April 1, 2025
Solengepras showed evidence of potential benefit in functional and non-motor symptoms versus placebo as measured by MDS-UPRDS Parts I, II, NMSS, and ESS, consistent with its novel non-dopaminergic mechanism of action This investigational treatment was …
Unity Consortium Kicks Off Adolescent Immunization Action Week (AIAW25) to Help Parents and Adolescents Stay on TASK with Recommended Immunizations
GlobeNewswire
·
April 1, 2025
AIAW 2025 Runs April 7-11 to Encourage Well-Visits and Recommended Immunizations VENTNOR CITY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- UNITY® Consortium, a non-profit dedicated to adolescent and young adult immunization and preventive health, urges …
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
GlobeNewswire
·
April 1, 2025
The clinical trial is designed to evaluate the safety, tolerability and efficacy of Clearmind’s innovative, psychedelic-derived, MEAI-based compound in individuals with alcohol addiction Vancouver, Canada, April 01, 2025 (GLOBE NEWSWIRE) -- Clearmind …
Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations
GlobeNewswire
·
April 1, 2025
PARSIPPANY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new landmark publication in the Mayo Clinic Proceedings. The …
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
April 1, 2025
Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in EuropeOperating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focusBERKELEY, Calif. and MAINZ, Germany, …
Nkarta to Participate in an April Investor Conference
GlobeNewswire
·
April 1, 2025
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 24th …
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
GlobeNewswire
·
April 1, 2025
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of …
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
GlobeNewswire
·
April 1, 2025
NEEDHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
Phathom Pharmaceuticals Announces Leadership Succession
GlobeNewswire
·
April 1, 2025
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven …
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
GlobeNewswire
·
April 1, 2025
– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company,” NASDAQ: CHRS) announced …
electroCore to Participate at the Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
ROCKAWAY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place …
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
GlobeNewswire
·
April 1, 2025
HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid …
Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference
GlobeNewswire
·
April 1, 2025
DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the …
Inspire Medical Systems, Inc. to Report First Quarter 2025 Financial Results on May 5, 2025
GlobeNewswire
·
April 1, 2025
MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the first quarter 2025 after the close of trading on Monday, May 5. Inspire’s management team will host a corresponding …
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics …
FeraMAXᴹᴰ est la marque de supplément de fer que les pharmaciens et les médecins au Canada recommandent le plus souvent depuis dix années consécutives
GlobeNewswire
·
April 1, 2025
MISSISSAUGA, Ontario, 01 avr. 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », titre à la Bourse de croissance TSX : RX) est fière d’annoncer que FeraMAXMD est la marque de supplément de fer la plus recommandée au Canada selon un sondage pancanadien …
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Tenth Consecutive Year
GlobeNewswire
·
April 1, 2025
MISSISSAUGA, Ontario, April 01, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX® is the #1 recommended iron supplement brand in Canada, based on a national survey of Canadian pharmacists and …
Merus nimmt an Kamingespräch auf der 24. jährlichen Needham Virtual Healthcare Conference teil
GlobeNewswire
·
April 1, 2025
UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Unternehmen für klinische Onkologie, das innovative, multispezifische Antikörper in voller Länge und Antikörper-Wirkstoff-Konjugate ( …
Merus participera à une discussion informelle lors de la 24e conférence annuelle Needham Virtual Healthcare
GlobeNewswire
·
April 1, 2025
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachussets, 01 avr. 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), entreprise spécialisée en oncologie développant des anticorps de pleine longueur multispécifiques et des conjugués anticorps-médicament …
Advanced Medical Balloons presents results from HYDRA-PMCF study of hygh-tec®, demonstrating high performance and safety
GlobeNewswire
·
April 1, 2025
HYDRA-PMCF-study evaluated hygh-tec®, a new polyurethane fecal management system hygh-tec® showed a high level of sealing performance (no leakage in 89.3%) and was safe to use (94.2% no signs of infection; GLOBIAD score = 0+1A) Full results will be …